Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1

Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1

AbstractContext Cholangiocarcinoma with highly heterogeneous, aggressive, and multidrug resistance has a poor prognosis. Although babaodan (BBD) combined with cisplatin improved non-small cell lung cancer efficacy, its impact on overcoming resistance in cholangiocarcinoma remains unexplored.Objectiv...

Full description

Bibliographic Details
Main Authors: Jiong Li, Xiangjun Ma, Faying Xu, Yuanliang Yan, Weiqing Chen
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Pharmaceutical Biology
Subjects:
Apoptosis
DNA damage
glutathione
yes-associated protein 1
Online Access:https://www.tandfonline.com/doi/10.1080/13880209.2024.2331060

Internet

https://www.tandfonline.com/doi/10.1080/13880209.2024.2331060

Similar Items